Pharmaceuticals & Biotech Dutch Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Dutch Investing Ideas
APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis
Pharming’s growth story leans on finding and treating more people with a very rare immune condition, but new research and genetic testing may take longer to turn into real patients than investors hope. With its older allergy medicine facing tougher competition and several big studies still years away, the next phase could hinge on whether the pipeline delivers on time.Read more
Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside
Pharming’s growth story leans on two rare-disease medicines: one that keeps serving the sickest patients, and another that’s quickly finding new patients and could soon be used in younger children. The upside depends on wider testing and diagnosis, while competition, trial setbacks, and pricing pushback could slow the momentum.Read more
Cell Therapy Exit And Single Late Stage Asset Will Drive Weaker Long Term Earnings
Catalysts About Galapagos Galapagos is a biotech company that is repositioning itself as a lean, cash rich platform focused on external business development and a limited internal pipeline. What are the underlying business or industry changes driving this perspective?Read more
Rare Disease Expansion Will Drive Durable Long Term Upside In This Biotech
Catalysts About Pharming Group Pharming Group is a commercial-stage biotech company focused on developing and marketing innovative therapies for rare and ultra-rare diseases. What are the underlying business or industry changes driving this perspective?Read more
Clinically Derisked Oncology Assets And Gilead Partnership Will Drive Long Term Earnings Potential
Catalysts About Galapagos Galapagos is repositioning as a capital rich, business development driven biotech company focused on acquiring and advancing clinically derisked assets. What are the underlying business or industry changes driving this perspective?Read more
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
Catalysts About Galapagos Galapagos is a biotechnology company focused on using its substantial capital base and deal-making expertise to build a differentiated, late stage therapeutic pipeline. What are the underlying business or industry changes driving this perspective?Read more
